Person: Reshma Kewalramani

Asia Leaders

Reshma Kewalramani Broadened Vertex Beyond Cystic Fibrosis. Launch Economics Are the Next Clinical Test

Reshma Kewalramani has placed high-value rare-disease medicines, internally discovered small molecules, gene editing and disciplined reinvestment of cystic-fibrosis cash flow at the centre of the strategy. The next phase will test capital discipline, execution and durability across Asia.

Asia Leaders

Reshma Kewalramani Is Betting Vertex’s Balance Sheet on a US$10 Billion Endocrine Expansion

Vertex’s agreement to buy Crinetics for about US$10 billion is Reshma Kewalramani’s largest strategic wager. The deal could accelerate non-cystic-fibrosis revenue, but its financing, integration and peak-sales assumptions now demand unusually close scrutiny.

Asia Leaders

Reshma Kewalramani Is Taking Vertex Beyond Cystic Fibrosis. The Diversification Must Now Become Durable

Vertex is moving from one dominant franchise towards pain, blood disorders and kidney disease. Reshma Kewalramani’s challenge is to preserve focus while building new commercial systems.